https://www.selleckchem.com/pr....oducts/ly3039478.htm
25 [95% confidence interval 1.13, 1.39]) and COVID-19 hospitalization or death (HR 1.35 [1.10, 1.66]). DMARDs and prednisone, but not RA autoantibody seropositivity, as well as black race, Hispanic ethnicity, and several chronic conditions were associated with COVID-19 and COVID-19 hospitalization or death. Patients with RA are at higher risk for COVID-19 and COVID-19 hospitalization or death than non-RA. With a COVID-19 risk that approaches other recognized chronic conditions, these findings suggest RA patients should be prioritized
Like
Comment
Share
